Navigation Links
Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial

SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%, p=0.0025 a 16% Relative Risk Reduction ) in acute coronary syndromes patients undergoing planned invasive treatment (either PCI or CABG).* Although patients undergoing invasive procedures are at greater risk of bleeding, these results were achieved without a significant increase in major bleeding compared to clopidogrel (11.5% vs 11.6%, p=0.88). Patients with planned invasive procedures at randomization accounted for more than 70% of the greater than 18,000 patients in PLATO. These sub-analysis data were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Additional findings from this PLATO invasive sub-analysis showed that treatment with ticagrelor, compared to clopidogrel, demonstrated an effect consistent with the results for the entire invasive subgroup across the multiple secondary efficacy endpoints. The effect was seen regardless of whether a standard 300 mg loading dose of clopidogrel was given, or an additional loading dose of clopidogrel (e.g. 600 mg) was given. Specifically, results in this subgroup analysis indicated treatment with ticagrelor:

  • Reduced CV death 3.4% vs. 4.3% (p=0.025) Relative Risk Reduction of 18%
  • Reduced myocardial infarction (heart attack, MI) 5.3% vs. 6.6% (p=0.002) Relative Risk Reduction of 20%
  • Reduced definite stent thrombosis 1.0% vs. 1.6% (p=0.003) Relative Risk Reduction of 38%
  • Reduced total mortality 3.9% vs. 5.1% (p=0.01) Relative Risk Reduction of 19%

"The majority of patients rushed to the hospital with severe chest pain or heart attacks will have an invasive procedure," said Christopher Cannon, M.D., PLATO Executive Committee member, a cardiologist at Brigham and Women's Hospital in Boston. "Doctors need to make quick decisions about antiplatelet therapy for patients who are sent for cardiac catheterization and may need angioplasty or surgery. In this study population, ticagrelor led to fewer heart attacks and deaths without a significant increase in major bleeding versus clopidogrel."

Similar to the overall PLATO findings, Dyspnoea (shortness of breath) was more common among patients on ticagrelor but less than 1% discontinued ticagrelor treatment in the sub-analysis because of dyspnoea.

The PLATO study was designed to reflect how patients with ACS are currently managed in clinical practice, by including patients who underwent invasive procedures and those who were managed with medication only.

Last month, the primary results from PLATO were presented at the European Society of Cardiology and simultaneously published in The New England Journal of Medicine in August 2009.

AstraZeneca remains on track to submit BRILINTA to regulatory authorities in the fourth quarter of this year.

About PLATO:

PLATO (A Study of PLATelet Inhibition and Patient Outcomes) was a head-to-head 18,624 patient outcomes study of ticagrelor plus aspirin versus the active comparator, clopidogrel plus aspirin, and was designed to establish whether ticagrelor could achieve meaningful cardiovascular and safety endpoints in ACS patients, above and beyond those afforded by clopidogrel, an irreversible therapy in the thienopyridine class of medicines. The study design of PLATO was published in the April 2009 edition of the American Heart Journal.

The bleeding definitions used within the PLATO trial were an evolution from the CURE bleeding definitions and were developed by the PLATO Executive Committee as constituting the most appropriate and clinically meaningful assessment of bleeding complications associated with acute and chronic therapy. The PLATO bleeding definitions provide a framework to allow investigators to record all bleeding events reported by patients in the PLATO trial. The bleeding definitions were developed to characterize bleeding in both the acute and long-term setting.

Given the size of the PLATO database, AstraZeneca will continue to analyze and publish additional PLATO findings.



Ticagrelor (BRILINTA(TM)) is an investigational oral antiplatelet treatment for ACS. BRILINTA (ticagrelor) is a reversibly binding oral adenosine diphosphate (ADP) receptor antagonist. It selectively inhibits P2Y(12), a key target receptor for ADP. ADP receptor blockade inhibits the action of platelets in the blood, reducing recurrent thrombotic events.

BRILINTA is the first in a new chemical class, the CPTPs (cyclo-pentyl-triazolo-pyrimidines) and is chemically distinct from the thienopyridines, such as clopidogrel and prasugrel.

AstraZeneca has proposed the name BRILINTA(TM) in the US. If approved by the FDA it will serve as the trade name for ticagrelor. BRILINTA is a trademark of the AstraZeneca group of companies.

*About Invasive Strategies for Acute Coronary Syndromes

Percutaneous coronary intervention (PCI) is a procedure to open existing blocked arteries, also known as angioplasty. Coronary artery bypass graft (CABG) is a procedure where surgeons bypass the affected artery in the heart.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
2. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
3. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
4. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
5. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
6. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
7. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
8. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
9. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
10. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
11. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Post Your Comments:
(Date:10/9/2015)... Lilly and Company (NYSE: LLY ) and Locemia ... Locemia,s intranasal glucagon, a potential treatment for severe hypoglycemia ... which is currently in Phase III clinical trial testing, ... hypoglycemia. --> --> ... formulation that is delivered in an emergency situation using ...
(Date:10/9/2015)... CHAPEL HILL, N.C. , Oct. 9, 2015 ... Pharmaceutical or Medical Device environments, corporate communications is ... external communications, corporations and professionals must continuously adjust ... the effectiveness of these adjustments is difficult, but ... to today,s communication options. ...
(Date:10/9/2015)... Regulatory affairs groups within medical device organizations face ... --> These specialized groups are charged with ensuring that ... pertaining to the development and marketing of medical device products. ... on their own internal effectiveness and efficiencies to remain productive ... --> --> Optimal resourcing and staffing ...
Breaking Medicine Technology:
... DIEGO , May 6 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... financial results for the first quarter ended March 31, 2010 on ... followed by a live webcast and conference call at 5:00 p.m. Eastern ... Orexigen management will ...
... , May 6 DUSA Pharmaceuticals, Inc. ( DUSA ) announces that its corporate ... 6:30 a.m. to be followed by a conference call at 8:30 a.m. , ... - 8:30 a.m. E.T. , , , ... , , 800-647-4314 , ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic ... elite developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. ... Over Heels girls team head coach and executive director, said. “It's a stepping stone ...
(Date:10/9/2015)... , ... October 09, 2015 , ... On Saturday, September ... World Jump Rope Championship in Madrid, Spain. Representing both the USA and Sweden in ... Double Unders and One-Minute Am Front Crosses, she was awarded 1 Silver and 4 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance has ... community improvement initiative that involves working with a series of local charities throughout ... Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE ...
(Date:10/9/2015)... ... October 09, 2015 , ... "As a nurse, I care for male ... "They have to wear large diapers or pads. We came up with this as ... to absorb urine leaking from the tip of the penis. This prevents stains from ...
(Date:10/9/2015)... ... October 09, 2015 , ... MMJ PhytoTech ... with Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates ... MMJ Phytotech Limited (MMJ) – a global leader in the field of commercializing ...
Breaking Medicine News(10 mins):
... Points Out Fundamental Flaw That May ... Plans to Achieve this Objective, CEDAR KNOLLS, N.J., ... a company specializing in,portable electronic medical records management solutions, ... support for,the adoption of electronic medical records (EMR) to ...
... Webcast -, CHICAGO, Feb. 4 Advanced ... biopharmaceutical company engaged in the,discovery, development and commercialization ... cancer and respiratory diseases, today,announced that its Chairman ... "Antibiotics: Super Drugs Against Super Bugs" panel at ...
... a brain area to later learning deficits , , MONDAY, ... doctors identify children exposed to alcohol during pregnancy but ... with the exposure, a new study suggests. , ... temporal pairing of a conditioned stimulus, such as a ...
... Gap, with the help of,influential fashion stylist Katie Grand, ... a new version of Mulberry,s iconic Roxanne,bag for the ... in,the UK and Paris on December 1, 2007 to ... collection curated by Katie, bringing together a,diverse array of ...
... U.S. Pharmacopeia (USP) is pleased to announce that ... compendia, the United States Pharmacopeia and National Formulary ... edition for 2008, USP 31NF 26, provides specifications ... excipients, dietary supplements, biologics and other therapeutics. , ...
... safe to wait to make a,decision about having prostate ... the doctor appointments and test results? Or will the,additional ... that men can take the time they need to ... Men,s Health Watch., One study evaluated men newly ...
Cached Medicine News:
Microwell EIA for the detection of EPO (Erythropoietin)...
Microwell EIA for detection of Calcitonin...
... PREMIUM SURGICLIP II™ single use ... Super Interlock™ clips., ,The ... applier has application in many ... occlude vessels and other tubular ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
Medicine Products: